[Azlocillin--a new anti-pseudomonas penicillin. A review of the literature and pharmacokinetic studies].
We studied the pharmacokinetics of azlocillin in 11 healthy persons following an i. v. infusion of 5 g over 30 minutes. The azlocillin concentrations in serum and urine were measured microbiologically. The serum concentrations averaged 530.5 (+/- 79.2) mg/l at the end of the infusion and 9.4 (+/- 4.3) mg/l six hours later. 73.8% of the dose was excreted in the urine during a period of six hours. The serum concentrations of azlocillin were analysed using a two-compartment model, and the pharmacokinetic constants were calculated by a computer. The average biological half-life (beta-phase) of azlocillin was 70.2 (+/- 7.8) min, the plasma clearance was 1.869 (+/- 0.284) ml/sec and the distribution volume (Vd area) was 11.34 (+/- 2.05) l, i. e. 0.17 l/kg.
D000328:Adult; D001390:Azlocillin; D006801:Humans; D007263:Infusions, Parenteral; D007700:Kinetics; D010406:Penicillins / Q000097:blood / Q000378:metabolism* / Q000494:pharmacology; D011549:Pseudomonas / Q000187:drug effects*
D010406:Penicillins; D001390:Azlocillin
Azlocillin--Ein neues Anti-Pseudomonas-Penicillin. Literaturübersicht und eigene pharmakokinetische Untersuchungen.